COOPER COMPANIES INC
For the period ended Apr 2, 2025. Filed Feb 19, 2025.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Apr 2, 2025 · Filed Feb 19, 2025
Contents
Pay Versus Performance Table
The following table provides disclosure for the indicated fiscal years regarding (i) the compensation paid to our Principal Executive Officer (“PEO”), and the average compensation of the other non-PEO NEOs (“Other NEOs"), as reported in the Summary Compensation Table (“SCT”), (ii) the “compensation actually paid” (“CAP”) to our PEO and Other NEOs, (iii) our company performance, and (iv) the performance of our peers.
The amounts provided are calculated pursuant to Item 402(v) of Regulation S-K. The OCC does not utilize “compensation actually paid” as a basis for making compensation decisions.
| FiscalYear · SCT TotalCompensationfor PEO (1)($) · CompensationActually Paidto PEO(1) (3)($) · AverageSCT Total Compensation for Other NEOs (2)($) · AverageCompensationActually Paidto Other NEOs (2) (3)($) · Value of Initial Fixed $100 Investment Based On: · Net Income (5)(in millions)($) · CompanySelectedMeasure: | ||||||||
|---|---|---|---|---|---|---|---|---|
| TotalStockholderReturn (4)($) · Peer GroupStockholderReturn (4)($) · Non-GAAPEPS (6)($) | ||||||||
| 2024 | 15,427,631 | 39,832,969 | 3,767,148 | 8,460,906 | 131.30 | 130.04 | 392.3 | 3.69 |
| 2023 | 13,490,923 | 22,309,137 | 3,462,463 | 4,997,872 | 97.77 | 99.33 | 294.2 | 3.20 |
| 2022 | 11,735,964 | (9,232,263) | 3,122,556 | (1,008,290) | 85.72 | 102.28 | 385.8 | 3.11 |
| 2021 | 10,994,906 | 36,205,083 | 2,772,601 | 7,944,570 | 130.69 | 132.08 | 2,944.7 | 3.31 |
(1)Our PEO for all presented fiscal years was Albert G. White III.
(2)Our Other NEOs for each year were Brian G. Andrews, Daniel G. McBride, Holly R. Sheffield, and Gerard H. Warner III.
| 56 | CooperCompanies 2025 Proxy Statement |
(3)Total compensation reported for our PEO and the average compensation of the Other NEOs for each fiscal year in the 2024 SCT was adjusted in accordance with Item 402(v)(2)(iii) of Regulation S-K to calculate “compensation actually paid” as follows:
| FY 2024 · FY 2023 · FY 2022 · FY 2021 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CEO($) · Average forOther NEOs($) · CEO($) · Average forOther NEOs($) · CEO($) · Average forOther NEOs($) · CEO($) · Average forOther NEOs($) | |||||||||||
| SCT Total Compensation | 15,427,631 | 3,767,148 | 13,490,923 | 3,462,463 | 11,735,964 | 3,122,556 | 10,994,906 | 2,772,601 | |||
| Adjustments for Equity Fair Value: | |||||||||||
| Deduct: equity award valuereported in the SCT | (12,480,056) | (2,437,453) | (10,569,853) | (2,212,547) | (9,250,214) | (2,000,105) | (8,499,660) | (1,700,029) | |||
| Add: year-end fair value (FV) of awards granted during the FY and remaining unvested at FY end | 15,357,812 | 2,999,501 | 11,289,458 | 2,192,652 | 6,953,597 | 1,503,562 | 18,414,809 | 3,685,523 | |||
| Add/(Deduct): change in year-end FV of prior year awards remaining unvested at FY end | 18,697,796 | 3,627,552 | 5,603,219 | 1,074,119 | (17,482,099) | (3,405,635) | 13,119,132 | 2,709,109 | |||
| Add/(Deduct): change in FV from prior FY end of prior-year awards that vested during FY | 2,910,971 | 565,558 | 2,487,221 | 477,940 | (1,224,000) | (261,639) | 2,193,605 | 493,591 | |||
| Adjustments for Pension Value: | |||||||||||
| (Deduct): aggregate change in actuarial present value of the RIP | (101,721) | (83,389) | (12,647) | (18,474) | — | — | (51,121) | (46,458) | |||
| Add/(Deduct): prior service cost attributed to benefits under the RIP | 20,536 | 21,989 | 20,816 | 21,719 | 34,489 | 32,971 | 33,412 | 30,233 | |||
| Compensation Actually Paid in FY: | 39,832,969 | 8,460,906 | 22,309,137 | 4,997,872 | (9,232,263) | (1,008,290) | 36,205,083 | 7,944,570 | |||
Equity values are calculated in accordance with ASC 718. The SCT value of stock options relies on a Black-Scholes Model and the year-end value of stock options used for determining CAP was calculated using the Hull-White Lattice Model. For a discussion of valuation assumptions, see Note 9, Stock Plans, in our Notes to Consolidated Financial Statements included in our 2024 Annual Report.
(4)Reflects cumulative total stockholder return (“TSR") of the Company and of the S&P 500 Healthcare Equipment Index assuming a $100 investment on October 31, 2019 and the reinvestment of all dividends.
(5)This column presents the Company's consolidated net income as reported in our Annual Report on Form 10-K for each covered year.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.